Brief: Can-Fite Anti-Obesity Drug Namodenoson Received Patent Allowance In Australia
04/11/2024 15:16
Nov 4 (Reuters) - Can Fite Biopharma Ltd CANF.TA :
* CAN-FITE ANTI-OBESITY DRUG NAMODENOSON RECEIVED PATENT
ALLOWANCE
IN AUSTRALIA
* CAN FITE: PATENT APPLICATION ACCEPTED BY AUSTRALIAN PATENT
OFFICE AND EXPIRES IN 2040
Source text: ID:nGNXbG4pz8
Further company coverage: CANF.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Can Fite Biopharma
See all newsBrief: Corrected-Can Fite Biopharma Ltd Files For Offering Of Up To 6.6 mln Ordinary Shares By Selling Shareholders
Can-Fite BioPharma rises after longer-than-anticipated overall survival in ongoing liver cancer study
Can-Fite BioPharma reports longer-than-anticipated overall survival in ongoing liver cancer study
Brief: Can Fite Biopharma Can-Fite Submits Phase 2 Study Protocol For Piclidenoson In Lowe Syndrome
Can-Fite rises as skin drug study reaches interim analysis stage